KPIs & Operating Metrics(New)
Cash Flow Statement
Growth Metrics

Bausch Health Companies (BHC) EBITDA (2016 - 2026)

Bausch Health Companies' EBITDA history spans 18 years, with the latest figure at -$950.0 million for Q1 2026.

  • On a quarterly basis, EBITDA fell 444.2% to -$950.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $587.0 million, a 61.91% decrease, with the full-year FY2025 number at $1.8 billion, up 17.27% from a year prior.
  • EBITDA hit -$950.0 million in Q1 2026 for Bausch Health Companies, down from $474.0 million in the prior quarter.
  • Over the last five years, EBITDA for BHC hit a ceiling of $619.0 million in Q3 2025 and a floor of -$950.0 million in Q1 2026.
  • Historically, EBITDA has averaged $225.1 million across 5 years, with a median of $285.0 million in 2022.
  • Biggest five-year swings in EBITDA: skyrocketed 2171.43% in 2024 and later tumbled 444.2% in 2026.
  • Tracing BHC's EBITDA over 5 years: stood at -$236.0 million in 2022, then soared by 253.39% to $362.0 million in 2023, then soared by 54.14% to $558.0 million in 2024, then decreased by 15.05% to $474.0 million in 2025, then plummeted by 300.42% to -$950.0 million in 2026.
  • Business Quant data shows EBITDA for BHC at -$950.0 million in Q1 2026, $474.0 million in Q4 2025, and $619.0 million in Q3 2025.